REGENXBIO Inc.
RGNX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $499 | $423 | $367 | $393 |
| - Cash | $59 | $80 | $130 | $58 |
| + Debt | $77 | $272 | $80 | $82 |
| Enterprise Value | $517 | $615 | $317 | $418 |
| Revenue | $30 | $21 | $89 | $21 |
| % Growth | 39.2% | -76% | 319.6% | – |
| Gross Profit | -$32 | $12 | $86 | $15 |
| % Margin | -107.9% | 57.3% | 96.1% | 70.2% |
| EBITDA | -$45 | -$56 | $19 | -$38 |
| % Margin | -151% | -262.1% | 20.9% | -177.9% |
| Net Income | -$62 | -$71 | $6 | -$51 |
| % Margin | -208.3% | -331.8% | 6.8% | -241.3% |
| EPS Diluted | -1.2 | -1.38 | 0.12 | -1.01 |
| % Growth | 13% | -1,250% | 111.9% | – |
| Operating Cash Flow | -$56 | -$49 | $34 | -$32 |
| Capital Expenditures | -$0 | -$0 | -$1 | -$1 |
| Free Cash Flow | -$56 | -$50 | $33 | -$33 |